DFX Intelligence
Private Equity Intelligence
Firms, funds, people, portfolio companies and transactions from sworn filings and cited announcements, kept as a graph with a date and a source on every edge. Reported gross assets are never fund size, regulatory AUM is never dry powder, and a deal value prints only when someone disclosed it.
Transactions / In Vitro Technologies
Thompson Street Capital Partners Portfolio Company Bioreclamation Acquires In Vitro Technologies
Add-on acquisitionclosedadd-onannounced Jun 28, 2013closed Jun 28, 2013Fact
What happened
- Target
- In Vitro Technologies
- Platform
- Bioreclamationadd-on basis: Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, announced today that its portfolio company Bioreclamation has acquired Baltimore-based In Vitro Technologies, provider of hepatocyte cells and other in vitro research tools to support the screening of drug compounds in early-stage drug discovery and development.
- Control
- Control
- Share acquired
- unknown
- Industry
- unknown
- Target location
- unknown
- Seller kind
- unknown
- Rollover
- unknown
Values, only where disclosed
- Enterprise value
- Not disclosed
- Purchase price
- Not disclosed
- Equity value
- Not disclosed
- Target revenue
- Not disclosed
- Target EBITDA
- Not disclosed
- Multiple
- Not disclosed
Parties and roles
3 named
Buy side
- “Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, announced today that its portfolio company Bioreclamation has acquired Baltimore-based In Vitro Technologies, provider of hepatocyte cells and other in vitro research tools to support the screening of drug compounds i”
- “Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, announced today that its portfolio company Bioreclamation has acquired Baltimore-based In Vitro Technologies, provider of hepatocyte cells and other in vitro research tools to support the screening of drug compounds i”
Side not stated
- “Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, announced today that its portfolio company Bioreclamation has acquired Baltimore-based In Vitro Technologies, provider of hepatocyte cells and other in vitro research tools to support the screening of drug compounds i”
Evidence
“Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, announced today that its portfolio company Bioreclamation has acquired Baltimore-based In Vitro Technologies, provider of hepatocyte cells and other in vitro research tools to support the screening of drug compounds in early-stage drug discovery and development.”
Press release wires (PR Newswire, GlobeNewswire, Business Wire public pages and RSS)confidence 80%recorded Sep 15, 2026